Fatty liver disease has been termed as a silent epidemic affecting over 25% of the global population. However, most of the people affected by non-alcoholic fatty liver disease (NAFLD) remain oblivious as the disease usually manifests at an advanced irreversible stage of non-alcoholic steatohepatitis (NASH). For the treatment of fatty liver and many other liver diseases (e.g., hepatitis) as well as the study of drug metabolism, drug uptake, or liver toxicity of various pharmaceutical and chemical compounds, the best in vitro model is built using primary human hepatocytes. Hepatocytes are the major cell type of liver and are responsible for most of the functions the liver is attributed for, such as the metabolism of food and drugs, synthesis of urea and albumin, removal of toxins, and production of cholesterol. Hence, hepatocytes isolated from the human liver represent the liver functions more accurately than any other cell type and are the gold standard for in vitro liver modeling. ATCC now provides HepatoXcell? primary human hepatocytes for use in disease research and drug discovery. Currently, the HepatoXcell? portfolio offers three different types of primary hepatocytes based on their plate-ability: HepatoXcell? Pro and Plus cells can be cultured for 7 and 3 days, respectively, and HepatoXcell? Eco are suitable for suspension culture. To support the growth and maintenance HepatoXcell? primary human hepatocytes, ATCC also offers three different hepatocyte media: Hepatocyte Thaw Medium helps to enrich viable cells after thawing the cryopreserved hepatocytes, and Hepatocyte Plating Medium and Maintenance Medium enable hepatocyte initiation and maintenance, respectively. Researchers around the globe are now able to use ATCC’s HepatoXcell? hepatocytes for their in vitro hepatic modeling. Learn more: https://ow.ly/1wQs50Vf517
